Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-176P is a **pseudogene** in the U6 small nuclear RNA family, which means it is a nonfunctional genetic relic derived from the canonical U6 snRNA gene. U6 snRNA itself is an integral and highly conserved component of the spliceosome, which catalyzes the removal of introns from precursor mRNA in eukaryotic cells[1][2][3]. Pseudogenes of U6, including RNU6-176P, often display sequence similarity to functional U6 snRNA genes but are not transcribed into active RNA or provide any known biological activity. Pseudogenes such as RNU6-176P are common in vertebrate genomes due to gene duplication and retrotransposition events but are generally considered nonfunctional[3][5]. There is no evidence they act as therapeutic targets, have associated drugs, play a role in disease, or are tracked as biomarkers. If you require information on the functional U6 snRNA instead, it is classified as a **small nuclear RNA** involved in splicing, but RNU6-176P (as indicated by “pseudogene”) is not its active form[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 176, pseudogene (RNU6-176P).